We used human umbilical cord segments as an ex vivo model to investigate the possible clinical diagnostic and therapeutic applications of microbubbles (MBs). 
M icrobubbles (MBs) are 2-to 8-m acoustically active particles consisting of a gaseous core surrounded by a biocompatible shell typically composed of a mix of lipids, albumin, or polymers. The resonant properties of MB make them a powerful class of ultrasound contrast agents with both diagnostic and therapeutic applications. In this regard, MBs can be modified by the conjugation to their shell of specific ligands, such as peptides or monoclonal antibodies, to create sitetargeted MBs able to detect molecular changes in endothelium (e.g., inflammation, thrombosis, angiogenesis) (1). Insonation of MBs can produce transitory micropores at cell membranes (2) , offering the possibility of delivering bioactive substances or genetic material into surrounding cells, a procedure termed sonoporation (3) .
To date there have been several reports of ultrasound (US) imaging of MBs and sonoporation in human vascular monolayers cultured in vitro (4, 5) . Using a human ex vivo model based on umbilical cord segments, we evaluated real-time US molecular imaging of MBs targeted either to a general endothelial surface receptor (CD9) or a marker of inflamed endothelium (intercellular adhesion molecule [ICAM]-1) and assessed the feasibility of sonoporation for the delivery of functional plasmids to the endothelium of a human vessel.
M E T H O D S
Microbubble preparation. Biotinylated lipidencapsulated perfluorocarbon MBs were purchased (Targeson LLC, Charlottesville, Virginia). Microbubbles were prepared following manufacturer's instructions at a final concentration of 4 to 5 ϫ 10 6 MBs per milliliter in saline solution, as determined with a hemocytometer XT-1800i (SYSMEX, Mundelein, Illinois). Alternatively, a vial of SonoVue (Bracco International B.V., Amsterdam, the Netherlands) was resuspended following the manufacturer's instructions (8 l of sulphur hexafluoride per milliliter).
Ultrasound image acquisition from umbilical cord segments. The veins of umbilical cord segments were cannulated and washed with a heparinated solution (20 UI/ml). Paired segments from the same cord were treated as follows: one was filled with 199 medium containing growth factors and the other with medium with 100 ng/ml tumor necrosis factor (TNF)-␣ to induce inflammatory conditions. Both segments were incubated 20 h at 37°C and were then immersed in a saline bath at 37°C for MB perfusion using an automated infusion syringe pump (VueJect [BR-INF 100, Bracco Research SA, Geneva, Switzerland]) and image acquisition. Segments were scanned with a Vivid i digital cardiovascular ultra-portable ultrasound system (GE Healthcare, Milwaukee, Wisconsin) with an i12LR high-frequency linear transducer (up to 13 MHz, using 4.5 to 9.9 MHz with second harmonic). Solutions of MB (2 to 5 million MB per milliliter in a total volume of 10 ml) were perfused using a pump at 1.6 ml/min. Video sequences were stored and subsequently analyzed with EchoPac 6.3 software (GE Healthcare).
Sonoporation of endothelium in intact human umbilical cord blood vessels. For sonoporation, the Vivid i digital ultrasound system with a different transducer (S3 multifrequency) (GE Healthcare) was used. A solution of SonoVue mixed with 20 g/ml plasmid deoxyribonucleic acid (DNA) was introduced into the lumen of umbilical arteries, and the vessels were tied off at both ends. Insonation was performed at harmonic imaging (1.7 to 3.4 MHz) at a high frame rate (112 Hz) and at a high mechanical index (1.3) for ϳ5 min. After insonation, artery segments were maintained for 20 h in growth factor supplemented medium 199, fixed in 4% paraformaldehyde, and processed for tissue microscopy analysis. In the case of umbilical vein experiments, 10 ml of the same mixture of MB and complementary DNA were perfused with a VueJect pump (Bracco Imaging, Milan, Italy) at a rate of 1.6 ml/min across human endothelial veins with simultaneous insonation that used the same frequency and mechanical index but a frame rate between 25 and 35 Hz. Then, endothelial cells were isolated from the vein (6) immediately after insonation and cultured for 20 h before being fixed in 4% paraformaldehyde and prepared for cellular microscopy analysis (Online Appendix). Institutional Review Board approval for the studies was obtained from the National Center of Cardiovascular Research and Hospital Universitario de la Princesa (IRB00005840). 
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Barreiro et al. Human Endothelial MB Targeting and Transfection conditions. Monolayers of primary human umbilical vein endothelial cells (HUVECs) were either left under resting conditions or were activated with the proinflammatory cytokine TNF-␣ and then mounted in an inverted parallel flow chamber for MB attachment evaluation by optical microscopy.
To test specific endothelial targeting, biotinylated Targestar B MBs were coupled to an antibody against CD9 (a cell-surface protein highly expressed in HUVECs) (Fig. 1A) (7) . For controls, we used naked (nonantibody-coupled) biotinylated MB and biotinylated MB coupled to an isotype-matched antibody raised against the adhesion molecule ICAM-3 (whose expression is hardly detectable in HUVECs) (Fig.  1A) . The MBs were drawn across the HUVECs at increasing flow rates, and the numbers of attached MB at each flow rate were counted and compared between different treatments (Figs. 1B and 1C). Nonspecific binding was assessed by the binding of MBs to plates coated with the substratum used for HUVEC cultures (fibronectin) and was very low in all cases.
We found that MBs coated with anti-CD9 (anti-CD9-MB) bound strongly to resting and activated HU-VEC monolayers, showing up to 9-fold greater binding than controls. The exponential phase of binding lasted up to 2 dynes/cm 2 . The MB binding was impaired by the increasing shear stress at high flow rates; however, there was no significant detachment during the experiment and the subsequent washout, indicating strong attachment. Isotype-control MBs and naked MBs showed some residual nonspecific binding that decreases with the increase of flow rate (Fig. 1B) .
Real-time echography imaging of MB-mediated vascular targeting in ex vivo human umbilical cord veins.
Having validated endothelial targeting of MB in the in vitro flow chamber, we next evaluated vascular MB targeting in an ex vivo model of human macrovascular tissue, the umbilical cord vein. Umbilical veins in cord segments were perfused with anti-CD9-MB, and images were collected throughout the experiment until after the last washout. We found that MB remained acoustically active after conjugation with antibody, and individual MBs attached to the vein wall were even detected with submillimetric resolution. During the washout period, the umbilical vein was fully coated with MB, delineating the vein wall. To rule out nonspecific adhesion, parallel control experiments were conducted with the ICAM-3-targeted and naked MBs; no significant attachment of MB was detected in either case ( Fig. 2A) . Quantitative analysis of contrast-enhanced US video intensity clearly demonstrated the specificity of anti-CD9-MB binding compared with the residual adsorptive attachment of control antibody-coupled or naked MB (Figs. 2B and 2C).
Detection of inflamed endothelium by MB-mediated
targeting. CD9 is constitutively expressed in endothelial cells, and its membrane expression is not significantly altered by proinflammatory stimulation (7) . Accordingly, treatment of umbilical cord veins with proinflammatory stimuli (TNF-␣) produced no change in the specific targeting of anti-CD9-MB (data not shown). To specifically target inflamed vascular beds, we conjugated MBs to an antibody against the adhesion molecule ICAM-1, which is up-regulated during inflammation. The effectiveness of the inflammatory activation was confirmed by isolating HUVECs from TNF-␣-treated umbilical veins and determining the platelet/endothelial cell adhesion molecule (PECAM)-1/(CD31)-ICAM-1/(CD54) double-positive population by fluorescence-activated cell sorting; cell-surface expression of ICAM-1 after TNF-␣ treatment was increased 2-fold with respect to resting conditions (Fig.  3A) . Ultrasound imaging of ICAM-1-targeted MB barely detected basal ICAM-1 expression in resting umbilical cords, whereas a 10-fold increase in MB binding was observed in inflamed tissue, demonstrating the ability of the technique to identify sites of local inflammation in the macrovasculature (Fig. 3B) .
Analysis of tissue integrity after US insonation at high mechanical index. To achieve efficient in situ transfection of DNA plasmids directly into intact endothelium, we attempted to induce transitory micropores in the luminal endothelial membrane of umbilical vessels by destroying MBs with sustained high-power insonation (mechanical index: 1.2 to 1.4). Before proceeding with transfection, we first assessed the effect of the insonation on tissue integrity by immunohistochemical analysis. Hematoxylin and eosin staining revealed no apparent tissue deterioration with US insonation (Fig. 4A) . Immunostaining of CD31/ PECAM-1 and 4',6-diamidino-2-phenylindole (DAPI) staining for nuclei confirmed that the integrity of the monolayer seemed to be preserved (Fig.  4B) . To test for possible changes in paracellular permeability, umbilical cord segments were incubated after insonation with fluorescein isothiocyanate (FITC)/dextran (77 kDa). Microscopy analysis of cryostat sections revealed an increase in paracellular permeability in US-treated cord samples compared with noninsonated cord samples. This increase was not significantly greater than that induced by our standard inflammatory treatment with TNF-␣ (Fig. 4C) .
Sonoporation of plasmid DNA in human umbilical cord veins and arteries. Having established that US application at high mechanical index does not produce .
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gross denudation of the endothelium, we evaluated the method for in situ sonoporation of complementary DNA plasmids. We first confirmed US-mediated MB destruction by optical microscopy or ultrasound imaging (data not shown). For sonoporation, a mixture of SonoVue MB and plasmid DNA encoding enhanced green fluorescent protein (EGFP) was included in the lumen of umbilical arteries and incubated under static conditions with simultaneous insonation. Confocal fluorescence analysis of arterial tissue revealed in situ EGFP expression in the endothelium 24 h after sonoporation (Fig. 5A) . Moreover, a mixture of SonoVue MB and ICAM-1-EGFP plasmid was perfused across umbilical veins with simultaneous insonation. Then, cells were isolated and cultured in vitro 24 h before microscopy analysis. In this way, we further confirm that delivered genes were correctly expressed because ICAM-1-EGFP was appropriately localized at the HUVEC plasma membrane, concentrated in microclusters and staining marginal microvilli (Fig. 5B) .
D I S C U S S I O N
The combination of US application with the administration of targeted MB is an attractive and well- Statistical analysis was performed using an unpaired t test with Welch's correction (p value shown in the figure). 
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balanced technique for both in vitro and in vivo use because of its noninvasive nature, its wide availability and relatively low cost, and its high spatiotemporal resolution, which provides sensitivity to low concentrations of targeted MB with a signal-to-noise ratio suitable for clinical use. Endothelial targeting offers great possibilities for detecting dysfunctional endothelium in atherosclerosis, vulnerable plaques, and processes associated with myocardial dysfunction such as ischemia/reperfusion or transplant rejection (8, 9) . Ultrasound contrast agents coupled to antibodies directed against specific vascular markers have been successfully applied in animal models during the last decade (10,11) to monitor endothelial damage or dysfunction (12) , inflammation (13), angiogenesis (14) , and thrombosis (15) . However, no study on human tissue has been reported previously.
To evaluate endothelial targeting with MB in intact human tissue, we performed experiments on the human umbilical cord vein and artery. The human umbilical vein is a good example of macrovasculature, having a similar caliber (5 to 8 mm) to other mediumsized vessels such as the renal artery or saphenous vein. The efficiency of MB targeting for a given concentration is probably lower in macrovessels than in smaller vascular beds because the likelihood of interaction with the vessel wall for each individual MB is much reduced. For this reason, we selected CD9 tetraspanin, a molecule that is a highly expressed marker in macrovasculature and microvasculature (16) , as well as in lymphatics (17), and we succeeded in detecting the entire luminal surface of the umbilical vein. CD9 plays an essential role in cell adhesion, proliferation and migration, platelet aggregation, and tumor metastasis (18) . Our group has also described a regulatory role for CD9 in the adhesion mediated by a variety of endothelial receptors (including vascular cell adhesion molecule [VCAM]-1 and ICAM-1) during leukocyte extravasation, a key event in the inflammatory response (7, 19) . This role suggests that localized release of blocking antibodies against CD9 might have potential as a general and more effective antiinflammatory therapy than the single inhibition of one of these adhesion molecules. However, CD9 is not only expressed by endothelial cells but also by a number of blood cell subsets (including platelets, neutrophils, and monocytes) (7, 20) . Therefore, the administration of CD9 blockers would require a localized release in inflammatory foci, which could be accomplished by their combination with antibodies against any inflammatory marker in the same MB.
Inflammation is a crucial component of many cardiovascular disorders from the earliest stages, and the potential of MB to identify sites of inflammation is therefore of great interest. In small animal models, inflammation can be visualized and quantified by introducing MB targeted to several well-established biomarkers such as P-selectin (21) or VCAM-1 (22) . Here, we have developed an ex vivo model of inflammation in human macrovasculature by using ICAM-1 as an inflammatory marker. We found that ICAM-1 is expressed at basal levels in resting endothelium, but this basal expression seems to be below the detection threshold of our imaging technique. Therefore, the anti-ICAM-1-tagged MB specifically highlighted the endothelium of vessels exposed to proinflammatory stimuli, validating this approach as a means of detecting inflammatory foci in large vessels.
The use of MB in combination with US has been shown to promote gene delivery in a variety of experimental animal models (reviewed in Miller et al. [23] ). Our ex vivo experiments in human umbilical cord vessels show that sonoporation is practicable in the human vasculature. However, the transfection efficiency was limited by the fact that the cells in the ex vivo model remain in a quiescent-like state, with low metabolic activity, which precludes a high protein yield from the transfected plasmid. Moreover, our experiments were performed with nontagged MB mixed with DNA in solution. The development of MB able to couple both antibodies and DNA at their outer surface might be critical for improving the efficiency of targeted sonoporation. It should also be noted that the sensitivity of our detection technique is lower than bioluminescence, for example. Nevertheless, our findings demonstrate the potential application of sonoporation in human tissue and thus constitute an important step toward the therapeutic use of noninvasive methods for gene therapy.
C O N C L U S I O N S
The human umbilical cord is a feasible ex vivo model for the study and development of therapeutic MB applications and also constitutes a unique and irreplaceable system to test for the functional specificity of antihuman antibodies. However, there are several limitations that cannot be overlooked, such as the fact that this model is a simplified ex-sanguine one in which the absence of blood cells and lack of physiologic flow could affect the binding of MB, and the requirement for humanized antibodies, peptides, or plasmids tested and approved by the Food and Drug Administration for clinical administration.
